TVR

DRUG3 trials

Sponsors

Janssen R&D Ireland, ViiV Healthcare

Conditions

Hepatitis CInfection, Human Immunodeficiency Virus

Phase 1

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

CompletedNCT01563328

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2012-03-01End: 2012-05-01Updated: 2017-03-28

Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

CompletedNCT01582035

Janssen R&D IrelandHepatitis C

Start: 2012-04-30End: 2013-11-30Updated: 2014-02-17

Phase 3

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

CompletedNCT01485991

Janssen R&D IrelandHepatitis C

Start: 2012-02-29End: 2014-04-30Updated: 2016-04-26

Related Papers

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

2014-12-0551 citations